News

Under the terms of the agreement, TG Therapeutics will make an up-front payment as well as make development and sales-based milestone payments and will pay a tiered single

The grant has been given to clinically advance Irofulven for the treatment of metastatic castration resistant prostrate cancer (mCRPC) by utilising a highly predictive biomarker for the drug

SuppreMol is involved in development of treatment options for autoimmune and allergic diseases. Besides owning and operating SuppreMol’s Munich operations, Baxter will also own SuppreMol’s complete early-stage development

CRPS is a condition characterised by severe pain in a limb, accompanied by autonomic, sensory, motor and trophic changes. In few patients, the chronic pain can lead to

Although the results from both placebo (36.5 mm improvement from baseline, p < 0.0001) and Tradipitant (40.5mm improvement from baseline, p < 0.0001) displayed significant and clinically meaningful

The acquisition includes assignment of certain patents and patent applications owned or controlled by the Swiss firm related to RNAi therapeutics. The deal also comprises of an exclusive

According to the company, the barcode on the overwrap is correct but the primary container barcode could be mislabeled with the barcode for Heparin Sodium 2000 USP units/1000mL

The two angiotensin-converting enzyme (ACE) inhibitors are approved by Health Canada and they will now be commercialized and manufactured locally by Valeant at its Laval, Quebec facility. Population

Under the deal, BMS will have an exclusive option to license and commercialize Prostvac, which is being developed to treat asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer